- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02955888
Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
A Phase 2, Double-Blind, Placebo Controlled Study to Evaluate the Safety & Tolerability of PBI-4050 and Its Effects on Pancreatic and Pulmonary Function in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a Phase 2, multi-center, double blind, placebo controlled study to evaluate the safety and tolerability of PBI-4050, and its effects on the pancreatic, pulmonary functions and on various biomarkers in Cystic Fibrosis patients with abnormal glucose tolerance. Patients with abnormal glucose tolerance have elevated glucose level either at 1 hour or 2 hour during an Oral Glucose Tolerance Test (OGTT).
A total of 90 patients will be enrolled for study participation. A Data Safety Monitoring Board (DSMB) will continually review individual patients safety data obtained from the 90 patients. When the first 15 patients have completed at least 1 month of study treatment, the DSMB will meet formally to determine whether additional patients may be enrolled, the study should continue with changes or if the study should be stopped. In addition, the DSMB will review the PK data and may recommend dose adjustment based on the PK results.
The total duration of study participation for each patient is at least 32 weeks, including up to 4 weeks of a screening period, 24 weeks of study treatment and 4 weeks of safety follow-up.
Patients who choose to participate in the open label extension will be in the study for an additional 24 weeks of study treatment and 4 weeks of safety follow-up (for a total of 56 weeks).
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Quebec, Canadá
- Institut Universitaire de Cardiologie et de Pneumologie de l'Université Laval (IUCPQ)
-
-
British Columbia
-
Vancouver, British Columbia, Canadá
- St. Paul's Hospital - Pacific Lung Health Centre (PLHC)
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá
- Queen Elizabeth II Health Science Center
-
-
Ontario
-
Ottawa, Ontario, Canadá
- Ottawa Hospital Research Institute
-
Toronto, Ontario, Canadá
- St. Michael's Hospital
-
-
Quebec
-
Montreal, Quebec, Canadá
- Institut de recherches cliniques de Montréal (IRCM)
-
Sherbrooke, Quebec, Canadá
- Centre de recherche du Centre hospitalier Universitaire de Sherbrooke
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patient is 18 years of age or older at screening.
- Patient has a documented and confirmed CF diagnosis.
- Patient has performed an OGTT for diagnosis of INDENT, IGT and de novo CFRD within 12 months prior to screening visit.
- Patient has a Body Mass Index (BMI) of at least 17 kg/m2.
- Patient has signed written informed consent.
- Patient is able and willing to self-monitor blood glucose level at home.
- Female patients of childbearing potential must have a negative pregnancy test (serum or urine) and agree to use adequate birth control from screening throughout the study and for the 30 days after the last study drug administration.
- If a male patient has not been vasectomized at least 6 months before screening and partners with a woman of childbearing potential, he must be willing to use an acceptable contraceptive method throughout the study and for the 30 days after the last study drug administration.
Exclusion Criteria:
- Patient has recent or ongoing infection requiring intravenous treatment with an anti-infective agent within 30 days before screening.
- Patient is concurrently taking high dose of ibuprofen (>30 mg/kg) or is using corticosteroids (except inhaled and topical corticosteroids).
- Patient is currently using weight-loss medications.
- 4. Patient has used any moderate/potent inhibitor of cytochrome P450 (CYP) 2C9 isozyme or strong inhibitor of CYP3A isozyme within 30 days prior to the first study drug administration.
- Patient has significantly elevated liver enzyme levels, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 Upper Limit of Normal (ULN) or total bilirubin above ULN at screening.
- Patient has a history of chronic alcohol or other substance abuse as determined at screening that may prevent study compliance based on Investigator judgment.
- History of malignancy of any organ system, treated or untreated, within the past 5 years other than basal or squamous cell skin cancer.
- Patient has unstable chronic heart failure that has required change in therapy within 2 months prior to screening.
- Patient with known non-controlled history of infection with Human Immunodeficiency Virus (HIV) and/or active Hepatitis.
- Woman who is pregnant, breast-feeding or planning a pregnancy during the course of the study.
- Woman of childbearing potential who is unwilling to use adequate birth control throughout the duration of the study.
- Patient has any condition that, in the Investigator's opinion, is likely to interfere with study conduct and compliance.
- Patient has participated in an investigational clinical trial within 30 days (or 5 half-lives, whichever is longer) prior to screening visit.
- Patient is under insulin and/or repaglinide treatment at screening/baseline
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: PBI4050
Quatro cápsulas de 200 mg (total de 800 mg) administradas por via oral, uma vez ao dia.
|
Investigational Medicinal Product
|
Comparador de Placebo: Placebo
Four 200 mg capsules (total 800 mg) administered orally, once daily.
|
Comparador
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Number of Subjects with Adverse Events (Combined Main Study and Extension Study Participation)
Prazo: Baseline to 1 Year
|
Adverse Event data (including abnormal laboratory values) collected up to final follow-up (30 days after last dose of study drug).
Serious Adverse Events that were ongoing at the follow-up visit will be followed until the event resolved, returned to baseline, or was determined to be a stable or chronic condition.
|
Baseline to 1 Year
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
---|---|
Change from Baseline in glucose level following Oral Glucose Tolerance Test (OGTT) (Combined Main Study and Extension Study Participation)
Prazo: Up to 1 Year
|
Up to 1 Year
|
Change from Baseline of insulin-secretion following Oral Glucose Tolerance Test (OGTT) (Combined Main Study and Extension Study Participation)
Prazo: Up 1 Year
|
Up 1 Year
|
Change from Baseline of HbA1C following Oral Glucose Tolerance Test (OGTT) (Combined Main Study and Extension Study Participation)
Prazo: Up to 1 Year
|
Up to 1 Year
|
Change from Baseline in pulmonary function parameters (FEV1 ) (Combined Main Study and Extension Study Participation)
Prazo: Up to 1 Year
|
Up to 1 Year
|
Change from Baseline in pulmonary function parameters ( FVC) (Combined Main Study and Extension Study Participation)
Prazo: Up to 1 Year
|
Up to 1 Year
|
Change from Baseline in pulmonary function parameters (FEV1/FVC ratio) (Combined Main Study and Extension Study Participation)
Prazo: Up to 1 Year
|
Up to 1 Year
|
Change from Baseline in pulmonary function parameters (Forced Expiratory Flow (FEF25%-75%)) (Combined Main Study and Extension Study Participation)
Prazo: Up to 1 Year
|
Up to 1 Year
|
Change from baseline in weight (Combined Main Study and Extension Study Participation)
Prazo: Up to1 Year
|
Up to1 Year
|
Outras medidas de resultado
Medida de resultado |
Prazo |
---|---|
Changes from baseline in fibrotic and inflammatory biomarkers in blood (Combined Main Study and Extension Study Participation)
Prazo: Up to 1 Year
|
Up to 1 Year
|
Changes from baseline in fibrotic and inflammatory biomarkers in urine (Combined Main Study and Extension Study Participation)
Prazo: Up to1 Year
|
Up to1 Year
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: John Moran, MD, Liminal BioSciences Ltd.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- PBI-4050-CT-9-07
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .